Table 3.
Test performance inputs in populations with different PSA levels
| % | Source | |
|---|---|---|
| Piflufolastat F 18 | ||
| Sensitivity—PSA ≤ 1.0 | 57.00 | OSPREY 2301a [20] |
| Sensitivity—PSA > 1.0 | 97.00 | OSPREY 2301a [20] |
| Specificity—PSA ≤ 1.0 | 93.00 | OSPREY 2301a [20] |
| Specificity—PSA > 1.0 | 55.00 | OSPREY 2301a [20] |
| Fluciclovine F 18 | ||
| Sensitivity—PSA ≤ 1.0 | 30.00 | Scarsbrook et al. 2020 [36] |
| Sensitivity—PSA > 1.0 | 85.00 | Scarsbrook et al. 2020 [36] |
| Specificity—PSA ≤ 1.0 | 67.00 | Bach-Gansmo et al. 2017 [37] |
| Specificity—PSA > 1.0 | 31.00 | Bach-Gansmo et al. 2017 [37] |
| PSMA 11 | ||
| Sensitivity—PSA ≤ 1.0 | 41.00 | Asokendaran et al. 2019 [38] |
| Sensitivity—PSA > 1.0 | 92.00 | Asokendaran et al. 2019 [38] |
| Specificity—PSA ≤ 1.0 | 67.00 | Expert opinion (same as fluciclovine F 18) |
| Specificity—PSA > 1.0 | 89.00 | Li et al. 2020 [40] |
| MRI | ||
| Sensitivity—PSA ≤ 1.0 | 18.00 | Expert opinion (same as CT) |
| Sensitivity—PSA > 1.0 | 68.00 | Expert opinion (+5% above CT) |
| Specificity—PSA ≤ 1.0 | 67.00 | Expert opinion (same as fluciclovine F 18) |
| Specificity—PSA > 1.0 | 53.00 | Li et al. 2020 [40] |
| SPECT | ||
| Sensitivity—PSA ≤ 1.0 | 10.00 | de Leiris et al. 2020 [39] |
| Sensitivity—PSA > 1.0 | 25.00 | de Leiris et al. 2020 [39] |
| Specificity—PSA ≤ 1.0 | 67.00 | Expert opinion (same as fluciclovine F 18) |
| Specificity—PSA > 1.0 | 31.00 | Expert opinion (same as fluciclovine F 18) |
| CT | ||
| Sensitivity—PSA ≤ 1.0 | 18.00 | Asokendaran et al. 2019 [38] |
| Sensitivity—PSA > 1.0 | 63.00 | Asokendaran et al. 2019 [38] |
| Specificity—PSA ≤ 1.0 | 67.00 | Expert opinion (same as fluciclovine F 18) |
| Specificity—PSA > 1.0 | 31.00 | Expert opinion (same as fluciclovine F 18) |
CT computed tomography, MRI magnetic resonance imaging, PSA prostate-specific antigen, PSMA prostate-specific membrane antigen, SPECT single-photon emission computerized tomography
aData on file, Lantheus